Making Next Generation Testing a Reality
Making Next Generation Testing a Reality
Natera’s test offerings are built upon a platform of cutting edge genetic science, advanced bioinformatics, and technical innovation. To ensure our tests are reliable and robust we require that all diagnostic and screening tests that we offer undergo rigorous pre-clinical and/or clinical validation.
PreNATUS (Prenatal Non-invasive Aneuploidy Testing Using SNPs)
This is a prospective blinded trial to demonstrate the accuracy of the Panorama™ test to detect genetic abnormalities (including Down syndrome) in a high-risk population by analyzing free floating fetal DNA found in maternal blood during pregnancy. This study is sponsored by Natera with partial grant funding support from the NIH, and is being led by Chief Investigator Dr. Ronald Wapner at Columbia University Medical Center. More than 30 other sites are participating including Stanford University, Massachusetts General Hospital / Harvard, Yale University, Mount Sinai School of Medicine, Carnegie Hill Imaging for Women, University of Perugia (Italy) and Montefiore Medical Center. Enrollment is now closed, and analysis is ongoing. To learn more about this study, including other participating centers, click here to view ClinicalTrials.gov.
This is a clinical utility trial designed to assess how non-invasive prenatal testing (NIPT) for aneuploidy should be integrated into the general population as a first line screen. More than 3,000 women from Rhode Island will be offered Panorama as part of their prenatal care, and the effect on care will be monitored and analyzed. This study is sponsored by Natera, and is being led by Chief Investigator Dr. Glenn Palomaki through Women and Infant’s Hospital, Rhode Island. Enrollment is ongoing. To learn more about this study, click here to view ClinicalTrials.gov.
Natera Microdeletions Registry
As part of this study, perinatal data and/or samples will be collected from 10,000 pregnant women whose physicians have ordered Natera’s commercially available Panorama™ prenatal test to assess positive predictive values, and to discover correlations between Panorama test parameters and obstetrical complications. Ten sites are expected to participate, and enrollment is planned to commence in the winter of 2014.
Prenatal Aneuploid Twin Samples
In order to establish the precise accuracy of the Panorama NIPT to detect aneuploidy in twin pregnancies, we are seeking to enroll any woman carrying a twin gestation pregnancy with a positive prenatal microarray or FISH test for a whole chromosome abnormality (such as Down syndrome) is eligible. Participation requires a blood sample from the mother as well as blood or cheek swab from the father (when possible).
To learn more about the prenatal aneuploid twins study, click here (PDF).
Prenatal Microdeletion Samples
In order to detect smaller, more atypical deletions in the Panorama NIPT microdeletions panel, including the 22q11.2 deletion (DiGeroge Syndrome), and to further extend the panel to cover new microdeletions, we are seeking to enroll any woman carrying a singleton pregnancy with a positive prenatal microarray or FISH test for a microdeletion/ duplication genetic abnormality. Participation requires a blood sample from the mother as well as blood or cheek swab from the father (when possible).
To learn more about the prenatal microdeletion study, click here (PDF).
Microdeletion / Aneuploidy Family Triad Samples
In order to continue to improve the accuracy of the Panorama NIPT to detect microdeletions in our current panel and to further extend that panel, we are seeking to enroll any couple who has a born child diagnosed with a chromosome abnormality such as Down syndrome, a microdeletion syndrome such as the 22q11.2 deletion (DiGeorge syndrome) or sex chromosome abnormalities such as Klinefelter syndrome through a positive microarray or FISH test is eligible. Participation requires a blood sample from the mother, a blood sample from the born child, and a blood or cheek swab sample from the biological father. These families are also welcome to contribute a blood or cheek swab sample from the biological father and a blood sample from an unaffected sibling(s) as well, although these are not required for participation.
To learn more about the family chromosome abnormality study, click here (PDF).
To learn more about the family microdeletion study, click here (PDF).
To learn more about the family sex chromosome abnormality study, click here (PDF).
Panorama NIPT for Aneuploidy - Target Sequencing Validation
This was a blinded clinical trial conducted by Dr. Kypros Nicolaides at King’s College of London Stanford University comparing Natera’s Panorama NIPT for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome), and Monosomy X (Turner syndrome) to karyotyping. The study results found no errors in more than 240 tests run, and validated the Panorama Test for clinical use. Results have been published in Prenatal Diagnosis, click here for a link to view the publication.
Panorama NIPT for Aneuploidy - High Risk and Low Risk Validation
In this larger clinical study, more than 1,000 samples were tested for Trisomy 21, Trisomy 18 Trisomy 13 and Monosomy X, further validating the methodology behind the Panorama test. Cooperating centers included Columbia University Medical Center, Stanford University School of Medicine, George Washington University, Mount Sinai School of Medicine, Carnegie Hill Imaging for Women, Baylor, Stanford University, and Yale University. Results have been published in Obstetrics & Gynecology, click here for a link to view the publication.
Panorama NIPT for Triploidy
This was a blinded clinical trial conducted by Dr. Kypros Nicolaides at King’s College of London demonstrating that Natera’s Panorama NIPT is able to detect triploidy, something that no other NIPT is able to do. Results have been published in Fetal Diagnosis and Therapy, click here for a link to view the publication.
Molecular Karyotyping of Products of Conception (POC) Following Miscarriage
This was a prospective study conducted by Stanford University comparing the ability of Parental Support technology, used in Natera’s Anora Test, to detect aneuploidy and maternal cell contamination in products of conception samples to traditional metaphase karyotype. Results have been published in PLoS One.